Idogen Q4’21: Glimpsing into 2022

Research Note



Redeye leaves its view on Idogen's report for the fourth quarter of 2021. The report did not contain any major surprises, and the company's efforts are mainly focused on advancing IDO 8 into a clinical asset. The phase l/lla-trial is scheduled for Q2 2022.


Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.